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Abstract
Aims: To assess the relationship between clinically maternal
chorioamnionitis and outcome in preterm very-low-birth
weight (VLBW) infants.
Methods: An observational case-control study was conduct-
ed in the neonatology departments of 12 acute care teaching
hospitals in Spain. Between January 2004 and December
2006, all consecutive VLBW (F1500 g) infants who were
born to a mother with clinical chorioamnionitis were
enrolled. The controls included infants who were born to
mothers without chorioamnionitis, matched by gestational
age, and immediately born after each index case. At a cor-
rected age of 24 months, a neurological examination and a
psychological assessment of the surviving children were
performed.
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Results: Sixty-six of the newborn infants died; therefore,
262 infants from the original sample were available for the
study. Follow-up data were obtained at a corrected age of
24 months from a total of 209 children (106 cases and 103
controls, 80% of the original sample size). Seventy children
(33.5%) were diagnosed with some type of sequelae. The
following conditions were all more prevalent in infants born
to mothers with chorioamnionitis in comparison to controls:
low development quotient (98.3"12.15 vs. 95.9"15.64;
Ps0.497), cerebral palsy (4.9% vs. 10.4%; Ps0.138), sei-
zures (1.0% vs. 3.8%; Ps0.369), and other neurological or
sensorial sequelae (32.0% vs. 34.9%; Ps0.611).
Conclusions: After controlling for gestational age, the study
population demonstrated that the neurological outcomes in
infants at a corrected age of 24 months was not worsened
by chorioamnionitis.
Keywords: chorioamnionitis; fetal membranes; follow-up;
infant; premature; premature birth; premature rupture.
Introduction
Infection and inflammation are often related to preterm birth.
Clinical, histological, and microbiological chorioamnionitis
are clear examples of infection and inflammation that are
related to birth and preterm birth dynamics. The greatest risk
of histological chorioamnionitis occurs when delivery takes
place at a gestational age of 23–24 weeks (79%) and grad-
ually decreases until 34 weeks (11%) w9x. In recent years,
significant attention has focused on the impact of antenatal
inflammation on both short-term outcomes and long-term
sequelae in preterm infants. In addition to severe acute mor-
bidity, including early-onset sepsis, necrotizing enterocolitis,
and lung disease w3, 10x, preterm infants have a considerably
increased risk of developing intraventricular hemorrhage and
periventricular leukomalacia. These complications, in turn,
are strong predictors of mental retardation and cerebral palsy
w6, 17, 18x. On the basis of a known association between
infection and very preterm birth, some authors proposed that
chorioamnionitis plays a causal role not only in the induction
of delivery but also in the fetal inflammatory response syn-
drome, which might cause acute morbidity and long-term
sequelae w6, 12x. Several studies have examined the effects
of clinical maternal chorioamnionitis and histological cho-
rioamnionitis on neonatal and neuro-developmental out-
comes in preterm babies w8, 13, 14, 16x; however, the
interpretation of these studies is confounded by gestational
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age, which was not adjusted in the analyses. Therefore, we
designed a multi-center, case-control study in which cases
and controls were matched by gestational age to assess the
relationship between maternal clinical chorioamnionitis and
neonatal outcomes at two-year follow-up in very-low-birth
weight (VLBW) preterm infants. The neonatal results were
recently published w2x.
Methods
Between January 2004 and December 2006, the neonatology depart-
ments at 12 acute care, university-affiliated hospitals throughout
Spain participated in this observational, prospective, and case-con-
trolled study. The cases consisted of consecutive preterm infants
who weighed -1500 g and born to a mother with a history of
clinical chorioamnionitis. The controls included infants born to a
mother without a history of chorioamnionitis, matched by gesta-
tional age, and immediately delivered after the corresponding study
case. Gestational age was determined by ultrasound examination at
8–10 weeks. The diagnoses of clinical chorioamnionitis in pregnant
women who presented with premature labor or premature rupture
of the membranes was based on the presence of uterine tenderness,
fever ()388C), leukocytosis ()12,000 cells/mm3), and increased
serum concentrations of C-reactive protein (CRP) ()30 mg/L).
CRP was determined at the time of patient care. A diagnosis of
chorioamnionitis was made based on the presence of one clinical
criterion (fever or tenderness) and at least one laboratory finding.
Infants with chromosomal or congenital anomalies were excluded
from the study. The study was approved by the institutional review
board of each participating center, and written informed consent for
data collection was obtained from the parents. The inclusion of cas-
es and controls in the study did not involve any intervention. Infants
received individualised, standard care in accordance with the current
clinical guidelines.
A study protocol was designed in which the following data were
prospectively recorded: maternal age, premature labor (persistent
uterine contraction, morphological changes in the cervix), premature
rupture of the membranes (PROM; determined by clinical or bio-
chemical evidence of a loss of amniotic fluid), antibiotic treatment
wused in 112 cases (88.5%) and 46 controls (52.3%)x, antenatal ster-
oid therapy (at least a single course of betamethasone), cesarean
delivery, multiple gestations, and whether or not the birth occurred
in a tertiary care center. Antibiotic treatment was started when
PROM was diagnosed and continued for five days or until delivery.
Newborn data were collected for the following characteristics: ges-
tational age, sex, birth weight, intrauterine growth restriction
(IUGR) (below the 10th percentile using race- and sex-specific
growth charts), the need for resuscitation with endotracheal intu-
bation, and Apgar score at 5 min. Neonatal morbidity and mortality
data included the presence of the following: respiratory distress syn-
drome, patent ductus arteriosus (and surgical correction), necrotizing
enterocolitis (and surgical treatment), seizures, early-onset sepsis,
late-onset sepsis, fungal sepsis, intraventricular hemorrhage, peri-
ventricular leukomalacia, bronchopulmonary dysplasia (BPD) or the
requirement of oxygen at 28 days, chronic lung disease or the
requirement of oxygen at a corrected age of 36 weeks of gestation,
retinopathy of prematurity of grade )2 (and laser treatment), death,
and survival without chronic lung disease. The length of the hospital
stay was also recorded.
At a corrected age of 24 months, a systematic neurological exam-
ination and a psychological assessment using a psychometric test
were performed on the surviving children (Bayley II or Brunet
Lezine). Data on weight, length, and head circumference in centi-
metres were measured at the time of assessment. Neuromotor func-
tions (walking, sitting, using hands, and head control), the presence
of seizures, vision (normal, the need for corrective lenses, no vision
or only light with one eye, or no vision or only light with both
eyes), auditory function (sensorineural or conductive hearing loss
or need for hearing aids), difficulty in communication (not under-
standing words, signs, or gestures), and difficulty in expression were
evaluated.
The Kolmogorov-Smirnov test was used to evaluate the distri-
bution of data. Normally distributed data are expressed as mean and
standard deviation (SD), and non-normally distributed data are
expressed as median and interquartile (25th–75th percentile) range.
Categorical variables are expressed as absolute numbers and per-
centages. Differences between cases and controls were assessed
using the Mann-Whitney U-test or a one-way analysis of variance
(ANOVA) for continuous variables and the x2-test for categorical
variables. SPSS, version 12.0 (SPSS Inc., Chicago, IL, USA), was
used for the statistical analyses, where in a P-0.05 was considered
statistically significant.
Results
Sixty-six of the newly-born infants died; therefore, 262
infants from the original sample were available for follow-
up at two-year. Follow-up data were obtained at the corrected
age of two years from a total of 209 children (106 cases and
103 controls), which is equivalent to 80% of the original
sample size. Seventy children were diagnosed with some
type of sequelae (33.5%).
To examine the comparability of groups, the characteris-
tics of both are summarized in Table 1. As expected, mothers
with chorioamnionitis received antibiotic therapy more often.
The groups are not strictly comparable since in the study
group a greater number were born in a university-affiliated
hospital, fewer were part of a multiple gestation, fewer births
occurred by cesarean section, the average Apgar score was
lower, and neonatal resuscitation with intubation was done
more frequently. These represent a greater risk of perinatal
asphyxia in the group without chorioamnionitis, which
would predispose these infants to further sequelae; however,
the sample is too small to interpret the effect of perinatal
asphyxia.
A total of 66 infants died during the perinatal period, spe-
cifically 28 in the chorioamnionitis group and 38 in the con-
trol group w2x. No infants died during the first two years of
life. Follow-up data were available for 209 infants, specifi-
cally 103 from the study group and 106 from the control
group. Fifty-three children were lost to follow-up; their per-
inatal characteristics are summarized in Table 2. A proper
analysis of outcomes should be conducted using the entire
cohort of patients and should not exclude patients who died
or were lost to follow-up. Table 3 depicts the perinatal and
neonatal data for the 119 infants who were not followed (66
dead and 53 lost to follow-up) and compares these cases (61)
to the controls (58). As expected, mothers in the chorioam-
nionitis group received more antibiotic treatment, and the
infants had a worse health status at birth (low Apgar scores
at 1 and 5 min after birth, requiring endotracheal intubation
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Table 1 Perinatal characteristics of the study group and the control group.
Study (ns103) Control (ns106) P-value
Corrected age (months) 24.7"2.33 25.1"2.68 0.168 NS*
Birth weight (g) 1109"236 1083"211 0.384 NS
Gestational age (weeks) 28.5"1.99 28.9"1.55 0.086 NS
Apgar 1 min 6.0"2.07 6.8"1.91 0.002
Apgar 5 min 7.9"1.24 8.5"1.34 -0.001
IUGR 9 (8.7%) 17 (16.0%) 0.110 NS
Male 54 (52.4%) 56 (52.8%) 0.953 NS
Multiple birth 22 (21.4%) 36 (34.0%) 0.042
Not born in a tertiary care center 4 (3.9%) 12 (11.3%) 0.043
No antenatal corticoids 8 (7.8%) 14 (13.9%) 0.161 NS
Antibiotic treatment 73 (93.6%) 32 (54.2%) -0.001
Cesarean 57 (55.3%) 75 (71.4%) 0.016
Intubation resuscitation 46 (44.7%) 33 (31.4%) 0.049
Hyaline membrane disease 57 (55.3%) 71 (67.0%) 0.084 NS
Persistent ductus arteriosus 30 (29.4%) 36 (34.3%) 0.452 NS
Necrotizing enterocolitis 6 (5.9%) 9 (8.6%) 0.456 NS
Intraventricular hemorrhage 18 (17.5%) 23 (21.9%) 0.422 NS
Grades III or IV 4 (3.9%) 7 (6.7%) 0.370 NS
Periventricular leukomalacia 19 (19.0%) 13 (12.5%) 0.202 NS
Retinopathy ()grade 2) 15 (15.2%) 10 (9.9%) 0.262 NS
Early-onset sepsis 5 (4.9%) 2 (1.9%) 0.277 NS*
Late-onset sepsis 37 (35.9%) 38 (36.9%) 0.885 NS
BPD (oxygen at 28 days) 37 (35.9%) 37 (35.2%) 0.918 NS
CLD (oxygen at 36 weeks PMA) 12 (12.0%) 19 (18.3%) 0.212 NS
*Using non-parametric or exact tests (Mann-Whitney U-test or Fisher’s exact test, respectively). IUGRsintrauterine growth restriction,
BPDsbronchopulmonary dysplasia, CLDschronic lung disease, PMAspostmenstrual age.
for resuscitation) and more frequently presented with early
sepsis. These results are similar to our previous data for the
entire study group w2x. These conclusions were the same
regardless of whether the analysis was performed separately
for infants who died (66) vs. those lost to follow-up (53) or
for the combined 119 infants.
The perinatal and neonatal medical histories of the infants
with and without follow-up were similar, and, therefore, the
sequelae are likely to be the same. Thus, it seems possible
to extrapolate the conclusions from the sample to the entire
population.
Follow-up results from the study group (chorioamnionitis)
and control group at the corrected (or postmenstrual) age of
two years are reported in Table 4.
Discussion
In this case-control study, premature infants born to mothers
with clinical chorioamnionitis, were not significantly differ-
ent than the control group at two-year of follow-up.
Several previous studies have related the presence of cho-
rioamnionitis to neurological sequelae or cognitive disorders.
Maternal chorioamnionitis may have lasting negative con-
sequences for fetal brain development, resulting in long-term
cognitive impairments even when major handicaps, such as
cerebral palsy, are absent w15x. In contrast, other data indi-
cated that chorioamnionitis alone should not be a causal fac-
tor in poor neurological outcomes. Neonatal morbidities,
Mental Developmental Index (MDI) scores, Psychomotor
Developmental Index (PDI) scores, probabilities of normal
MDI and PDI scores, and the prevalence of cerebral palsy
were compared between the chorioamnionitis and control
groups while controlling for gestational age, sex, and the
maternal use of steroids and/or antibiotics. The chorioamnio-
nitis group of 102 infants was compared to the 75 control
infants. In VLBW infants, we observed similar MDI and PDI
scores and similar risks of cerebral palsy in births affected
by chorioamnionitis and in those unaffected w11x. Recent
work has more strongly associated neurological sequelae
with gestational age in comparison to the presence of cho-
rioamnionitis. Neither surrogate indicators for, nor direct
markers of, in utero exposure to acute inflammation were
significantly associated with severe adverse outcomes; how-
ever, gestational age at delivery was significantly associated
with outcome. Among children born between 23 and
32 weeks of gestation, neonatal complications, gestational
age at delivery, and the caregiver’s intelligence quotient, but
not in utero exposure to acute inflammation, were factors
associated with increased risks of severe adverse neuro-
developmental outcomes at six years of age w1x.
Inflammation is the mechanism most widely implicated
in the onset of preterm and term labor, as well as in fetal
damage, Infection, and inflammation that act through bio-
chemical mechanisms. In many cases, histological chorioam-
nionitis is asymptomatic or has few clinical manifestations,
and pathogens may or may not be present in the amniotic
fluid. Cytokine release-induced inflammation in an infectious
process may have an important role in the genesis of pre-
mature labor, and inflammation is thought to play a patho-
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Table 2 Perinatal data for the populations with and without follow-up.
Followed Not followed P-value
(ns209) (ns53)
Birth weight (g) 1096"224 1112"229 0.649 NS
Gestational age (weeks) 28.7"1.79 28.5"1.75 0.485 NS*
Apgar 1 min 6.4"2.03 6.0"2.27 0.283 NS*
Apgar 5 min 8.2"1.32 8.4"1.60 0.136 NS*
IUGR 26 (12.4%) 3 (5.9%) 0.182 NS
Male sex 110 (52.6%) 22 (43.1%) 0.224 NS
Multiple birth 58 (27.8%) 15 (29.4%) 0.813 NS
Not born in a tertiary care center 16 (7.7%) 6 (12.0%) 0.394 NS*
No antenatal corticoids 22 (10.8%) 10 (20.4%) 0.069 NS
Antibiotic treatment 105 (76.6%) 28 (68.3%) 0.281 NS
Cesarean 132 (63.5%) 31 (60.8%) 0.723 NS
Intubation resuscitation 79 (38.0%) 22 (43.1%) 0.499 NS
Hyaline membrane disease 128 (61.2%) 28 (56.0%) 0.496 NS
Patent ductus arteriosus 66 (31.9%) 20 (40.8%) 0.234 NS
Necrotizing enterocolitis 15 (7.2%) 0 0.082 NS*
Intraventricular hemorrhage 41 (19.7%) 12 (25.0%) 0.415 NS
Grades III or IV 11 (5.3%) 2 (4.2%) 0.750 NS
Periventricular leukomalacia 32 (15.7%) 7 (14.9%) 0.892 NS
Retinopathy ()grade 1) 25 (12.5%) 4 (8.7%) 0.471 NS
Early-onset sepsis 7 (3.4%) 5 (9.8%) 0.064 NS*
Late-onset sepsis 75 (36.4%) 14 (28.0%) 0.263 NS
BPD (oxygen at 28 days) 74 (35.6%) 17 (34.7%) 0.907 NS
CLD (oxygen at 36 weeks PMA) 31 (15.2%) 10 (20.8%) 0.341 NS
*Using non-parametric or exact tests (Mann-Whitney U-test or Fisher’s exact test, respectively). IUGRsintrauterine growth restriction,
BPDsbronchopulmonary dysplasia, CLDschronic lung disease, PMAspostmenstrual age.
Table 3 Perinatal data for the 119 infants without follow-up (66 died and 53 lost to follow-up).
Study (ns61) Control (ns58) P-value
Birth weight (g) 1008"251 962"245 0.316 NS
Gestational age (weeks) 27.5"1.96 27.5"1.80 0.726 NS*
Apgar 1 min 4.9"2.35 5.9"2.31 0.015*
Apgar 5 min 7.2"2.24 8.0"1.76 0.023*
IUGR 4 (6.6%) 7 (12.5%) 0.271 NS
Male sex 32 (52.5%) 34 (60.7%) 0.368 NS
Multiple birth 17 (27.9%) 19 (33.9%) 0.478 NS
Not born in a tertiary care center 4 (6.7%) 6 (10.7%) 0.438 NS*
No antenatal corticoids 11 (18.0%) 8 (16.0%) 0.777 NS
Antibiotic treatment 44 (97.8%) 18 (54.5%) -0.001
Cesarean 29 (47.5%) 32 (57.1%) 0.299 NS
Intubation resuscitation 40 (66.7%) 25 (44.6%) 0.017
Hyaline membrane disease 44 (77.2%) 38 (69.1%) 0.333 NS
Patent ductus arteriosus 22 (39.3%) 24 (44.4%) 0.583 NS
Necrotizing enterocolitis 9 (15.8%) 5 (9.8%) 0.355 NS*
Intraventricular hemorrhage 26 (49.1%) 22 (42.3%) 0.488 NS
Grades III or IV 13 (24.5%) 14 (26.9%) 0.779 NS
Periventricular leukomalacia 7 (13.7%) 8 (16.0%) 0.748 NS
Retinopathy ()grade 1) 3 (12.0%) 4 (12.1%) 0.989 NS
Early-onset sepsis 12 (20.3%) 0 -0.001*
Late-onset sepsis 22 (40.0%) 13 (24.5%) 0.086 NS
BPD (oxygen at 28 days) 12 (42.9%) 12 (35.3%) 0.543 NS
CLD (oxygen at 36 weeks PMA) 6 (23.1%) 8 (25.0%) 0.865 NS
*Using non-parametric or exact tests (Mann-Whitney U-test or Fisher’s exact test, respectively). IUGRsintrauterine growth restriction,
BPDsbronchopulmonary dysplasia, CLDschronic lung disease, PMA, postmenstrual age.
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Table 4 Follow-up results at two years.
Study (ns103) Control (ns106) P-value
Weight (g) 11,337"1481 10,869"1465 0.024
Height (cm) 85.4"4.14 85.0"4.24 0.523 NS
Head circumference (cm) 48.1"2.77 47.9"1.94 0.392 NS*
Development quotient (%) 98.3"12.15 95.9"15.64 0.497 NS*
Cerebral palsy (CP) 5 (4.9%) 11 (10.4%) 0.138 NS
Type of CP: 0.487 NS
Diplegia 2 (40.0%) 3 (27.3%)
Hemiplegia 3 (60.0%) 4 (36.4%)
Tetraplegia 0 3 (27.3%)
Athetoid 0 1 (9.1%)
Seizures 1 (1.0%) 4 (3.8%) 0.369 NS*
Some sequelae 33 (32.0%) 37 (34.9%) 0.611 NS
Walking 6 (5.8%) 12 (11.3%) 0.157 NS
Sitting 0 4 (3.8%) 0.122 NS*
Hands 3 (2.9%) 8 (7.6%) 0.134 NS
Head 0 2 (1.9%) 0.498 NS*
Vision 7 (6.8%) 11 (10.6%) 0.334 NS
Hearing 10 (9.8%) 7 (6.7%) 0.411 NS
Communication 0 5 (4.7%) 0.060 NS*
Expression 18 (17.8%) 22 (21.4%) 0.525 NS
*Using non-parametric or exact tests (Mann-Whitney U-test or Fisher’s exact test, respectively).
genic role in periventricular leukomalacia and cerebral palsy
w12x. The use of antibiotics in pregnant women may change
the course of chorioamnionitis, although it fails to eliminate
the presence of pathogens in the amniotic fluid w5x. An early
diagnosis of chorioamnionitis, together with the use of anti-
biotics and corticosteroids, may moderate the process of
inflammation and improve neonatal and neurological long-
term outcomes. The most beneficial treatment protocol for
chorioamnionitis needs to be determined by a prospective
study and then instituted. To date, the combination of mater-
nal antibiotics and steroids appears most promising w7x. Cur-
rently, there does not appear to be a ‘‘silver bullet’’ that is
capable of preventing unfavourable neuro-developmental
outcomes in the setting of fetal and/or neonatal inflammatory
response. Thus, there is clearly a need for more epidemio-
logical studies using advanced techniques of laboratory
research and neuro-imaging and sufficiently long follow-ups.
It is hoped that these studies will identify pre- and postnatal
inflammatory risk profiles by clarifying the relationship
between inflammation markers and their expressions in fetal
and neonatal circulation over time. Although such research
will be complex, it is necessary for a successful development
of new anti-inflammatory interventions in the newborn w4x.
The findings of this study allow us to challenge the belief
that inflammatory factors play a pathogenic role in the neu-
rological injuries that are sustained by premature infants and
their subsequent sequelae of cerebral palsy and cognitive dis-
orders. This knowledge presents the possibility of improving
the prognoses of infants who suffer from premature labor,
PROM, and even maternal chorioamnionitis. It also supports
a more conservative obstetric management of these situations
because neonatal and long-term outcomes depend more on
gestational age at the time of delivery than on the presence
of chorioamnionitis.
This study sample is large enough and used sufficiently
strict selection criteria to be considered reliable. Moreover,
data collection was prospectively conducted. Both preterm
populations were comparable in gestational age and weight.
In the chorioamnionitis group, Apgar scores were lower and
more infants were born in a tertiary care center, more moth-
ers delivered vaginally, and there were more singleton ges-
tations than in the control group. These differences were
expected to be unfavourable for the study group, and, there-
fore, one would predict less favourable outcomes for these
infants. There is no other study to-date that analyzes clinical
chorioamnionitis using these characteristics. At follow-up,
over 80% of the initial population was analyzed, which gives
our study statistical reliability. Moreover, the analysis of neo-
natal pathology demonstrated that there were no differences
between the children who were studied at follow-up and
those who were lost; hence, we can extrapolate the results
to the entire original study population.
A limitation in all studies of chorioamnionitis is the dif-
ficult diagnosis. Making a diagnosis of clinical chorioamnio-
nitis is less precise than microbiological testing of the
amniotic fluid or pathologic examination of the membranes,
umbilical cord, and/or placenta. Unfortunately, there is no
gold standard for making the diagnosis. Histological findings
that are suggestive of chorioamnionitis in the placenta are
common in premature labor and become more common with
decreasing gestational age. The presence of pathogens in the
amniotic fluid by itself is not diagnostic of chorioamnionitis.
Clinical criteria can be confusing, but, if properly selected,
they are useful in practice and allow prospective inclusion
in studies like this.
In our study population, the only observed perinatal com-
plications that were found to be associated with clinical
maternal chorioamnionitis were lower Apgar scores, a more
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frequent need for resuscitation involving endotracheal intu-
bation, and an increased incidence of early-onset sepsis;
however, these complications and the presence of chorioam-
nionitis are not always accompanied by worse neurological
outcomes at a corrected age of two years.
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